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Annexin A5 Scintigraphy of Forearm as a Novel In Vivo
Model of Skeletal Muscle Preconditioning in Humans
Gerard A. Rongen, MD, PhD; Wim J.G. Oyen, MD, PhD; Bart P. Ramakers, MSc;
Niels P. Riksen, MD; Otto C. Boerman, PhD; Neil Steinmetz, MD; Paul Smits, MD, PhD
Background—Nonlethal ischemia and reperfusion reduce ischemia-reperfusion–induced cell death, a phenomenon called
ischemic preconditioning. In animal models, this potent endogenous protection is mimicked in vivo by administration
of adenosine. In humans, exploitation of ischemic preconditioning is hindered by the lack of an appropriate in vivo
model to study this phenomenon. To solve this problem, we aimed to set up an easy-to-use human in vivo model to study
ischemic or pharmacological preconditioning.
Methods and Results—Healthy male volunteers performed unilateral ischemic handgrip. At reperfusion, we intravenously
injected technetium-99m–labeled Annexin A5, a presumed marker of ischemic injury, and we imaged both forearms and
hands simultaneously with a gamma camera. Region of interest analysis (counts per pixel) and subsequent calculation
of the percentage difference in radioactivity between experimental and control hands (thenar muscle; meanSE)
revealed significant uptake to the ischemically exercised tissue (263% at 4 hours after reperfusion; P0.05). This
selective localization of Annexin A5 was reduced by ischemic preconditioning (10 minutes of ischemia plus reperfusion
before ischemic exercise) or by infusion of adenosine into the brachial artery to 61% and 103%, respectively
(P0.05 versus ischemic exercise alone), resembling observations in animal models with infarct size as an end point.
Appropriate control experiments supported our conclusion.
Conclusions—Annexin A5 scintigraphy can be applied to test pharmacological or physiological interventions for their
ability to prevent ischemia-reperfusion injury. (Circulation. 2005;111:173-178.)
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Ischemic preconditioning is defined as increased toleranceagainst ischemia-reperfusion injury resulting from a previ-
ous short exposure to ischemia.1 Since the original descrip-
tion of this phenomenon by Murry et al1 in 1986 in the canine
heart, the underlying mechanism of action has partially been
revealed.2 Ischemia-induced release of adenosine activates
adenosine receptors (A1 and A3) on cardiomyocytes, followed
by activation of protein kinase C, ultimately resulting in
opening of mitochondrial ATP-sensitive potassium channels.
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Influx of potassium and depolarization of the mitochondrial
inner membrane delay cell death during subsequent periods
of ischemia, probably by inducing a small increase in mito-
chondrial volume.3 Ischemic preconditioning reduces the
release of mitochondrial cytochrome C and prevents apopto-
sis.4–6 Whether this explains the full protective action of
ischemic preconditioning is not known. Apart from the heart,
other organs such as liver, brain, and skeletal muscle are
protected by ischemic preconditioning in various species such
as rat, pig, dog, and rabbit.7–9 These findings suggest a
universal endogenous protective phenomenon against the
deleterious sequelae of ischemia.
The mechanism underlying ischemic preconditioning sug-
gested the possibility of pharmacological modulation of cellular
tolerance to ischemia-reperfusion injury. In animal models,
various drugs that are currently used in clinical practice to
prevent or treat acute ischemic events interfere with ischemic
preconditioning or modulate ischemia-reperfusion injury. For
example, adenosine and opiates mimic ischemic preconditioning
(pharmacological preconditioning),10,11 whereas ATP-sensitive
potassium channel blockers and adenosine receptor antagonists
inhibit ischemic preconditioning.12 Insulin and statins reduce
ischemia-reperfusion injury by a mechanism that is, at least
partially, independent from the signal transduction pathway of
ischemic preconditioning.13,14 Knowledge of the effect of (car-
diovascular) drugs on ischemia-reperfusion injury will increase
rational pharmacotherapy in patients who are at risk for ischemic
events. Unfortunately, translation of these observations from
animals to humans is hindered by the lack of a specific model to
study ischemia-reperfusion injury in conscious humans in
vivo.15
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Recently, Annexin A5 scintigraphy has been developed to
detect early signs of cell death in humans in vivo.16,17
Annexin A5 is an endogenous protein that binds with high
affinity to negatively charged phosphatidylserine.18 Because
of an active translocase, phosphatidylserine is located almost
exclusively on the inner leaflet of the lipid bilayer of the
normal cell membrane. Early in the process of apoptosis, the
asymmetric distribution of phosphatidylserine is lost, and
phosphatidylserine is exposed on the outer surface of the cell,
thus providing binding sites for extracellular Annexin A5.19
In mice, 90 minutes of hindlimb ischemia followed by a
3-hour period of reperfusion induced apoptosis of vascular
cells and skeletal muscle fibers, which was reduced by a
caspase inhibitor.20 To the best of our knowledge, apoptosis
has not been studied after shorter bouts of ischemia combined
with exercise. After mild ischemia, reversible phosphatidyl-
serine externalization has recently been reported without
subsequent development of cell death.21 Therefore, we hy-
pothesize that a relatively short period of exercise during
local blockade of the circulation induces externalization of
phosphatidylserine and binding of Annexin A5, which can be
used to detect early and reversible ischemia-reperfusion injury.
The aim of this study was to validate Annexin A5 scintigra-
phy as a tool to detect ischemia-reperfusion injury in humans in
vivo. We reasoned that a relevant marker of ischemia-
reperfusion injury should also be able to detect the protective
effect of ischemic and pharmacological preconditioning with
adenosine. We selected forearm skeletal muscle for 3 reasons.
First, after intravenous administration of Annexin A5, the
nonischemic forearm could serve as an internal control to
subtract nonspecific background activity that results from circu-
lating radiotracer. Second, a validated model to detect ischemia-
reperfusion injury of forearm skeletal muscle would allow
efficient pharmacological screening by infusion into the brachial
artery of drugs that could potentially modulate tolerance to
ischemia-reperfusion injury. Finally, forearm ischemic load is
well defined by occlusion of the forearm circulation without
confounding by collateral circulation.
This study addresses 3 main questions: Does ischemic
isometric muscle exercise induce local targeting of radio-
labeled Annexin A5? Can this targeting be prevented by a
previous bout of ischemia and reperfusion (ischemic precon-
ditioning)? And finally, does local infusion of adenosine
protect against subsequent injury from ischemic exercise?
Methods
Subjects
After giving informed consent, 43 healthy male volunteers (age, 18
to 34 years) participated in 6 separate experiments. Subjects with
cardiovascular disease, hypertension (systolic blood pressure
140 mm Hg and/or diastolic blood pressure90 mm Hg measured
sphygmomanometrically in supine rest), or diabetes mellitus (fasting
glucose 7.0 mmol/L or random glucose 11.0 mmol/L) were
excluded. Volunteers were free of medications and were asked to
abstain from caffeine-containing beverages for 24 hours before the
start of the experiment. The protocol was approved by the Institu-
tional Review Board of UMC Nijmegen.
General Procedures
Volunteers were studied in the sitting position after cannulation of an
antecubital vein of the dominant arm for injection of radiolabeled
Annexin A5 (see below). Maximal voluntary contraction was deter-
mined in the nondominant arm with a handgrip dynamometer
(Baseline Hydrolic Hand Dynamometer, Fabrication Enterprise Inc).
Ischemic Exercise
In 10 volunteers (ischemic exercise [Isch Ex]), the circulation of the
nondominant forearm was occluded for 10 minutes with an upper
arm cuff inflated to 200 mm Hg. Immediately after occlusion of the
forearm circulation, ischemia was combined with isometric contrac-
tions of the finger flexors at 50% of maximum voluntary contraction.
These contractions were performed rhythmically: 5-second contrac-
tion followed by 5-second relaxation until the volunteer was ex-
hausted. The total duration of ischemia was 10 minutes independent
from the duration of contractions. Radiolabeled Annexin A5 (0.1 mg
protein, 500 MBq technetium [Tc]-99m) was administered intrave-
nously immediately after the start of reperfusion. Forearms were
imaged at 0, 1, 2, and 4 hours after injection. For this purpose, flexor
muscles of both forearms were positioned on the gamma camera
(Siemens Orbiter camera equipped with low-energy, high-resolution
collimators) in a pronated position and scanned simultaneously until
100 000 counts were detected. After imaging of the flexor muscles,
the palmar sides of both hands were placed on the gamma camera,
and images of 50 000 counts were detected.
Ischemic Preconditioning Followed by
Ischemic Exercise
In a separate group of 8 volunteers, ischemic exercise was preceded by
a 10-minute period of forearm ischemia and a 10-minute period of
reperfusion without simultaneous exercise (IPIsch Ex). Pilot studies
(data not shown) indicated that this period of ischemia without concom-
itant exercise did not induce targeting of Annexin A5. Immediately after
ischemic exercise, Annexin A5 was infused, and scintigraphic images
were performed as described for the Isch Ex group.
Adenosine Followed by Ischemic Exercise
In a third group of 9 volunteers, the brachial artery was cannulated30
minutes before drug infusion. In this group, adenosine (50 g · min1 ·
dL1 forearm tissue; Adenocor, Sanofi-Synthelabo Inc) was infused into
the brachial artery for 10 minutes beginning 20 minutes before the start
of the ischemic exercise (ADOIsch Ex). Immediately after ischemic
exercise, Annexin A5 was infused, and scintigraphic images were
performed as described for the Isch Ex group. In this group, the
measurement at 2 hours after reperfusion was omitted.
Phentolamine Followed by Ischemic Exercise
In a separate group of 10 volunteers, phentolamine (15 g · min1 ·
dL1 forearm tissue; Regitine, Novartis Pharma Inc) was infused
instead of adenosine to study the effect of vasodilation per se on
subsequent ischemia-reperfusion injury (PHENTIsch Ex). In this
group, the measurements at 0 and 2 hours after reperfusion were
omitted for logistical reasons. Otherwise, the same protocol as in the
ADOIsch Ex group was performed.
Uptake of Tc-99m–Labeled Albumin After
Ischemic Exercise
In an additional group of 3 volunteers, nonspecific mechanisms of
targeting such as changes in capillary permeability or blood flow
were explored. For this purpose, these individuals performed ische-
mic exercise as described above. Instead of Annexin A5, an
equimolar dose of Tc-99m–labeled albumin was injected immedi-
ately on reperfusion. Subsequently, the forearms were scanned at 1
and 4 hours after reperfusion as described above.
Delayed Injection of Annexin A5 After
Ischemic Exercise
Finally, the influence of timing of the Annexin A5 injection was
studied in 3 volunteers. This group performed ischemic exercise as
described above. In this group, Annexin A5 (0.1 mg protein, 500
MBq Tc-99m) was injected 1 hour after reperfusion instead of
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immediately on reperfusion. Both forearms were scanned immedi-
ately and 3 hours after injection of Annexin A5 (1 and 4 hours after
reperfusion) as described above.
Preparation of Radiopharmaceuticals
Radiolabeled Annexin A5 was freshly prepared before each experi-
ment by adding Tc-99m Pertechnetate (1500 MBq) in the presence of
stannous tricine to succininydylhydrazinonicotinamide (HYNIC)–
conjugated recombinant human Annexin A5 (NAS 2020, 0.275 mg
per vial; Theseus Imaging Corp). Radiochemical purity as checked
by instant thin layer chromatography was always95%. The labeled
Annexin A5 solution was filtered with a low-protein-binding
0.22-m filter (Millipore No. SLGV-0.25 BS, Millex GV). Finally,
500 MBq of the labeled Annexin A5 (0.1 mg) was further diluted
with NaCl 0.9% and immediately administered to the volunteer.
Radiolabeled albumin was prepared analogous to radiolabeled
Annexin A5. Human serum albumin (200 mg/mL; Cealb, Sanquin
CLB) was conjugated with HYNIC and stored in vials containing 0.6
mg HYNIC-conjugated albumin (approximately equimolar amount
of protein compared with the Annexin A5 vials). Radiolabeled
albumin was freshly prepared before each experiment by adding
Tc-99m Pertechnetate (1500 MBq) in the presence of stannous
tricine to a vial. Radiochemical purity as checked by ITLC was
always 95%. The labeled albumin solution was filtered with a
low-protein-binding 0.22-m filter (Millex GV). Finally, 500 MBq
of the labeled albumin (0.2 mg) was further diluted with NaCl 0.9%
and immediately administered to the volunteer.
Data Analysis
All the digitized gamma camera images were analyzed offline by the
same investigator (W.O.) using Siemens ICON software. Two
regions of interest were drawn in each forearm representing flexor
muscles and thenar muscles. Special care was taken to avoid the
major veins and arteries in the region of interest. Radioactivity was
expressed as counts per pixel. To correct for background activity, the
final result was expressed as the percentage difference between the
experimental (nondominant) arm and control arm (targeting):
targeting(ROI
experimental arm
ROIcontrol arm)100%/ROIcontrol arm, where
ROI represents region of interest (flexor or thenar muscle). The
effect of ischemic exercise on targeting of Annexin A5 was statis-
tically analyzed with a repeated-measures ANOVA with time as a
within-subject factor and group as a between-subject factor. For this
analysis, the first time point (immediately after reperfusion) was
excluded because of the confounding effect of postischemic reactive
hyperemia. Because this analysis revealed a significant interaction
between time and group, results were also expressed as a change in
targeting from 1 to 4 hours after reperfusion. For each time point,
post hoc analysis was performed with 1-way ANOVA followed by
Scheffé’s test for post hoc comparisons (SPSS for Windows, release
10.0.7, SPSS Inc). Pilot studies have shown that forearm blood flow
as measured by plethysmography increased from 51 to 333 mL
· min1 · dL1 forearm (n6, meanSE) directly after ischemic
exercise and reduced toward baseline levels within 1 hour.
Results
Groups were similar with respect to age, weight, height,
blood pressure, random plasma glucose concentration, max-
imal voluntary handgrip force, and duration of the ischemic
exercise. All volunteers quickly and uneventfully recovered
from the ischemic exercise.
Directly after injection of radiolabeled Annexin A5, a large
increase in activity was observed in all 3 groups in the thenar
muscles of experimental compared with the control arm
(694%, 638%, and 7813% in Isch Ex, IPIsch Ex, and
ADOIsch Ex, respectively; P0.50 for between-group
comparison, 1-way ANOVA). This initial increase almost
completely disappeared at 1 hour after reperfusion in all
groups and is interpreted as the result of postocclusive
hyperemia (the Table).
At the end of the subsequent 3 hours, the annexin labeling
in the ischemic hand of the Isch Ex group was 263% greater
than in the control hand. In contrast, after ischemic precon-
ditioning (IPIsch Ex) and after previous infusion of aden-
osine (ADOIsch Ex), this difference in activity further
decreased to 61% and 103%, respectively (the Table and
Figure 1). Consequently, the increase over time of Annexin
A5 targeting from 1 to 4 hours after reperfusion was signif-
icantly blunted in the IPIsch Ex and ADOIsch Ex groups
compared with the Isch Ex group (Figure 2).
To assess the effect of vasodilation per se, adenosine was
replaced by phentolamine (PHENT) in an extra series of
experiments. In this PHENTIsch Ex group, Annexin A5
targeting increased over time, resulting in a difference be-
tween the 2 hands of 257%, a number closely resembling
the results of the Isch Ex group. As a consequence, Annexin
A5 targeting in the PHENTIsch Ex group was significantly
higher compared with the IPIsch Ex and ADO-Isch Ex
group (the Table and Figure 2).
In contrast to Annexin A5, Tc-99m–albumin was not
retained in the experimental hand after ischemic exercise. The
difference in activity between the hands was 20.5% (range,
1% to 3%) and 01% (3% to 1%) at 1 and 4 hours of
reperfusion, respectively (n3) and significantly differed
from the Isch Ex group, in which Tc-99m–Annexin A5 was
used instead of albumin (meanSE; P0.01 for effect of
group; P0.05 for interaction between group and time,
repeated-measures ANOVA).
In a final control experiment, Tc-99m–Annexin A5 was not
injected directly after reperfusion but 1 hour later. With this
approach, Annexin A5 targeting to the thenar muscle was
Course in Annexin A5 Targeting
Time After Reperfusion, h
0 1 2 4
Thenar muscle
Isch Ex (n10) 694 191 232 263*
IPIsch Ex (n8) 638 93† 82‡ 61‡
ADOIsch Ex (n9) 7813 152    103‡
PHENTIsch Ex (n10)    217    257*§
Flexor muscle
Isch Ex (n10) 636 51 71 92*
IPIsch Ex (n8) 635 41 31 22
ADOIsch Ex (n9) 869 83    63
PHENTIsch Ex (n10)    72    82
Values shown are percent difference between experimental and control
sides (meanSE). Overall ANOVA for repeated measurements showed a
significant interaction between group and time (P0.000 and P0.006 for
thenar and flexor muscle, respectively).
*P0.01 for effect of time (ANOVA for repeated measurements; only t1
and t4 included in this analysis).
†P0.05, ‡P0.01 vs Isch Ex (1-way ANOVA, followed by Scheffé’s post
hoc test; PHENTIsch Ex was excluded from this analysis).
§P0.005 vs ADOIsch Ex for interaction between time and group
(repeated-measures ANOVA).
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only 72% (range, 5% to 11%) at 4 hours after reperfusion
(n3), which was significantly different from the 263%
(see the Table, Isch Ex group) when Annexin A5 was injected
immediately on reperfusion (P0.01 for effect of group,
repeated-measures ANOVA).
In general, targeting of radiolabeled Annexin A5 showed a
similar pattern for the flexor muscle, although less pro-
nounced than for the thenar muscle (the Table and Figure 2).
Results did not relevantly change when the statistical analysis
was refined with workload as a covariate.
Discussion
This study reveals 3 novel findings: (1) Ischemic handgrip
increases uptake of Annexin A5 in the hand and forearm; (2) this
targeting of Annexin A5 is prevented by a previous bout of 10
minutes of ischemia and 10 minutes of reperfusion (ischemic
preconditioning); and (3) intra-arterial infusion of adenosine
provided protection against ischemia-reperfusion injury (phar-
macological preconditioning). These observations were most
pronounced in the thenar muscle of the hand but also occurred in
the flexor muscle and resemble the effect of ischemic precondi-
tioning and intra-arterial infusion of adenosine on infarct size in
skeletal muscle of pigs after a more prolonged ischemic in-
sult.9,10 Thus, our observations are in accordance with our
hypothesis that Annexin A5 scintigraphy validly detects ische-
mia-reperfusion injury, ischemic preconditioning, and pharma-
cological modulation of ischemia-reperfusion injury.
We did not observe retention of radiolabeled albumin in
the experimental arm, indicating that the observed targeting
of Annexin A5 is not caused by nonspecific targeting such as
changes in vascular permeability or reactive hyperemia.
Delay of the Annexin A5 injection by 1 hour did not result in
uptake of Annexin A5. Finally, in a pilot study in 6 healthy
volunteers, the AV difference in plasma creatine kinase
activity across the experimental forearm did not change in
response to this ischemic exercise, excluding relevant skeletal
muscle necrosis (data not shown). Taken together, these
observations are fully compatible with a short-lasting avail-
ability of Annexin A5 binding sites after this relatively mild
ischemic stimulus and may provide an argument against the
occurrence of apoptosis in this model. This finding contrasts
with the long-lasting availability of Annexin A5 binding sites
after myocardial infarction or apoptosis as observed by
others.16,17,19,22 Our observation is in agreement, however,
with reversible availability of externalized phosphatidylser-
ines in response to mild hypoxia or ischemia as has been
reported by others.21,23,24
Alternatively, one might argue that targeting of Annexin A5 in
our experiments is driven mainly by reactive hyperemia. Although
this concept provides an explanation for the lack of uptake of
Annexin A5 when injected 1 hour after reperfusion, it does not
explain why Annexin A5 targeting was prevented by ischemic
preconditioning or adenosine infusion. Reactive hyperemia was
similar for the 3 groups, as reflected by a similar distribution of
Annexin A5 directly after reperfusion; nevertheless, significant
differences in retention of Annexin A5 were observed 4 hours after
reperfusion. Our interpretation that reactive hyperemia is not signif-
icantly involved in targeting of Annexin A5 after ischemic exercise
is further supported by the lack of uptake of Tc-99m–albumin. The
observed action of ischemic and pharmacological preconditioning
on Annexin A5 targeting after ischemic exercise closely resembles
the effect of these interventions on infarct size as demonstrated in
various animals and organs, including skeletal muscle,9,10,25 and a
clinical trial in the heart.26 This further indicates that this technique
detects relevant early signs of ischemic exercise and reperfusion-
induced injury and can be used for future pharmacological research
to evaluate agents intended to protect against ischemia-reperfusion
injury in humans in vivo.
Figure 1. Typical image of thenar (left) and flexor (right) muscle at 4 hours of reperfusion. Regions of interest are marked. In this indi-
vidual, percentage difference in radioactivity (counts per pixel) between experimental and control sides was 37% and 10% for thenar
and flexor muscle, respectively. In this particular experiment, ischemic exercise was performed without previous preconditioning. Exer-
cise is required during ischemia for targeting of annexin A5. In addition, distribution of radioactivity is in accordance with uptake in
muscle instead of bone or skin.
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In this study, we used phentolamine as a control vasodila-
tor for adenosine. In contrast to other vasodilators such as
nitric oxide donors or calcium channel blockers, phentol-
amine does not have a known direct effect on cellular
tolerance against ischemia-reperfusion injury. It should be
emphasized, however, that the vasodilator action of phentol-
amine is limited given a certain baseline -adrenergic tone.
We did not measure the vasodilator response to adenosine
and phentolamine in these experiments. It is well known from
previous studies with these drugs that forearm blood flow
measured with strain-gauge plethysmography increases by a
factor of 3 to 5 in response to phentolamine27,28 and by a
factor of 10 in response to adenosine.29 Therefore, our
observation with phentolamine indicates that an increase in
flow before ischemic exercise to 10 mL · min1 · dL1
forearm tissue does not affect Annexin A5 scans after
ischemic exercise. However, our observation does not ex-
clude that part of the protective action of adenosine could
involve vasodilation, eg, by increasing shear stress and
subsequent release of nitric oxide before the ischemic exer-
cise. Therefore, the mechanism of protection of exogenous
adenosine may be different from ischemic preconditioning.
However, this possibility also occurs in the animal studies
exploring the protective action of adenosine in the heart or
skeletal muscle with infarct size as an end point. The present
study was not intended to elucidate the mechanism of
adenosine-induced protection.
Models previously used to study ischemic preconditioning
in humans have important pitfalls. Epidemiological studies
have shown that preinfarct angina reduces infarct size.30–32
However, these studies may have been biased by differences
in reperfusion time, which is significantly shorter in patients
with preinfarct angina.33 Repeated PTCA reduces lactate
formation and ischemia-associated ECG changes. Like infarct
size in animal models, these surrogates for ischemia-
reperfusion injury are responsive to adenosine receptor an-
tagonists and glibenclamide.34,35 However, possible recruit-
ment of collateral circulation, which could be reduced by the
pharmacological treatment, complicates interpretation of
these observations. Changes in venous lactate do not neces-
sarily reflect differences in ischemic injury but may result
from differences in ischemic load. Observations in animals
indicate that ECG is a poor surrogate end point to detect
ischemia-reperfusion injury, especially when pharmacologi-
cal interventions such as glibenclamide interfere with the
electrophysiological properties of the sarcolemma.36 Finally,
repeated PTCA is a complicated procedure with inherent risk
that makes this model difficult to use for pharmacological
screening in humans in vivo. An elegant model of ischemic
preconditioning is restricted to patients undergoing coronary
artery bypass surgery.37 This limitation hinders efficient
screening of pharmacological or physiological interventions
for their potential to interfere with ischemic preconditioning
in conscious persons. In contrast to the limitations of these
methods, ischemic forearm exercise followed by Annexin A5
scintigraphy is not biased by collateral circulation, detects
membrane changes that directly result from ischemia-
reperfusion injury, and can easily be applied to volunteers
with minimal risk of serious complications.
In conclusion, Annexin A5 scintigraphy reliably detects
ischemia-reperfusion injury and a protective effect of inter-
ventions known to reduce infarct size in skeletal muscle. Our
observations support the use of this model as a possible
screen for pharmacological interventions that aim at reducing
ischemia-reperfusion injury in clinically relevant organs such
as the heart or brain. For this purpose, however, further
research, including elucidation of signal transduction path-
ways, is needed to validate extrapolation of findings in the
forearm to other organs.
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